Saturday 17 October 2026 Export XBIO’s income statement to Excel — free account

Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 19.0% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS grew 8.89% and free cash flow fell 128.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.98 0.03 −1.49%

Follow XBIO

Alert me

Market cap: $4.7M
P/E: 0.0×
Fwd P/E: −0.9×
Dividend yield: —
F-score: 5/9
Altman Z: −30.91
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 13.70%

Capital & Financial Ratios $m

Market Cap 4.71

Revenue 3.26

Net Income (2.48)

Free Cash Flow (2.31)

Net Debt (6.47)

Current Ratio 7.43

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.89)

P/S ratio 1.39

P/B ratio 0.75

Past 5Y EPS Growth —

This Y EPS Growth 20.62%

Next Y EPS Growth (62.75%)

Next Y revenue growth (23.33%)

Next 5Y EPS Growth 49.05%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 15.28%

10-year low 10-year high

P/B against its own 10 years 38.48%

10-year low 10-year high

EV/FCF against its own 10 years 26.04%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	9	6	8	6
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	10	7	8	7

	2023	2024	2025	Q'26
Payables	0	0	0	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	1	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	46.78%	20.36%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	1.13%	(9.55%)	(18.47%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	1	1	1	3
’24	1	1	1	1	3
’23	1	1	1	1	3
’22	0	0	0	0	2
’21	0	0	0	0	1
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	0	(1)	0	(2)
’24	(1)	(1)	0	(1)	(3)
’23	(1)	(1)	(1)	(1)	(4)
’22	(2)	(1)	(1)	(1)	(5)
’21	(2)	(1)	(1)	(1)	(5)
’20	(1)	(1)	(1)	(1)	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	0	(1)	0	(2)
’24	(1)	(1)	0	(1)	(3)
’23	(1)	(1)	(1)	(1)	(4)
’22	(2)	(1)	(1)	(1)	(5)
’21	(2)	(1)	(1)	(1)	(5)
’20	(1)	(1)	(1)	(1)	(4)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.20)	(0.41)	—	—	—
’25	(0.59)	(0.45)	(0.33)	(0.22)	(1.58)
’24	(0.78)	(0.83)	(0.28)	(0.68)	(2.57)
’23	(0.60)	(0.69)	(0.69)	(0.77)	(2.71)
’22	(1.20)	(1.90)	(0.60)	(1.00)	(4.60)
’21	(1.50)	(1.30)	(1.30)	(1.36)	(5.49)
’20	(1.90)	(1.50)	(12.00)	(1.50)	(17.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	396.00	210.00	164.28	9.30	4.40	12.10	2.40	2.55	2.78	1.90	Analyst estimates 2026–2028 Powerpack
	High	2,039.41	708.00	1,074.00	390.00	58.50	56.80	13.80	7.50	5.20	13.93
People
People	Employees	7	5	4	4	4	4	4	4	2	2
	Revenue/emp, $m	0.43	1.52	0.00	0.00	0.11	0.29	0.43	0.64	1.25	1.49
Income, $m
Income, $m	Revenue	3	8	—	0	0	1	2	3	3	3
	Gross margin, %	100.00	97.94	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(54)	(4)	(7)	(13)	(14)	(6)	(7)	(4)	(4)	(3)
	EBT margin, %	(1,806.87)	(47.40)	0.00	(74,707.60)	(3,161.36)	(486.36)	(383.88)	(162.78)	(158.39)	(90.07)
	Net income	(54)	(4)	(7)	(13)	(11)	(6)	(7)	(4)	(4)	(3)
	Depreciation	1	0	0	3	0	0	0	—	—	—
Per share, $
Per share, $	Revenue	48.47	105.06	0.00	0.06	0.68	1.13	1.20	1.66	1.62	1.75
	Earnings	(941.18)	(49.22)	(96.04)	(63.30)	(17.00)	(5.10)	(4.60)	(2.71)	(2.57)	(1.58)
	Cash flow	(141.96)	20.70	(85.50)	(22.44)	(6.68)	(4.61)	(3.27)	(2.69)	(1.83)	(1.34)
	Capex	(0.27)	(0.13)	0.30	0.01	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(142.23)	20.57	(85.20)	(22.43)	(6.68)	(4.61)	(3.27)	(2.69)	(1.83)	(1.34)
	Book value	261.22	198.08	131.12	60.36	19.11	17.90	9.59	6.41	3.90	4.35
	Shares, m	0	0	0	0	1	1	1	2	2	2
Valuation, ×
Valuation, ×	P/E	0.00	0.00	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	—	0.48	29.85	11.42	2.54	2.15	2.46	1.24
	P/B	2.48	1.15	—	0.24	1.07	0.72	0.32	0.56	1.02	0.50
	EV/Sales	0.00	0.00	—	(0.60)	6.06	(3.32)	(4.47)	(0.94)	0.45	(1.03)
	EV/FCF	(4.22)	8.08	—	0.80	(0.62)	0.81	1.64	0.58	(0.40)	1.34
Cash, $m
Cash, $m	Operating cash flow	(9)	1	(6)	(6)	(4)	(5)	(5)	(4)	(3)	(2)
	Capex	0	0	0	0	—	—	—	—	—	—
	Free cash flow	(9)	1	(6)	(6)	(4)	(5)	(5)	(4)	(3)	(2)
Balance, $m
Balance, $m	Working capital	6	4	0	10	11	17	13	9	6	7
	Total debt	—	—	—	0	0	0	—	—	—	—
	Net debt	(4)	(6)	(1)	(10)	(12)	(18)	(13)	(9)	(6)	(8)
	Shareholders’ equity	16	14	10	17	12	18	14	10	6	7
Returns, %
Returns, %	ROA	(307.49)	(17.91)	(43.46)	(100.39)	(62.74)	(34.22)	(37.95)	(32.65)	(45.24)	(35.12)
	ROIC	(245.91)	(25.63)	(49.03)	(117.66)	(1,266.33)	(2,389.72)	(763.68)	(347.32)	0.00	0.00
	ROE	(511.45)	(23.60)	(60.31)	(133.18)	(74.05)	(36.89)	(40.91)	(35.28)	(50.13)	(40.01)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RVPH Reviva Pharmaceuticals Holdings, Inc.	$5.0M	— (loss-making)	—	—	n/m	+57.80% (above 0%: growing)	—	0.00%	Compare
LGVN Longeveron Inc.	$4.8M	— (loss-making)	— (loss-making)	−9.18% (below 0%: shrinking)	n/m	−49.12% (below 0%: shrinking)	63.41%	(2,150.17%)	Compare
XBIO Xenetic Biosciences, Inc.	$4.7M	— (loss-making)	— (loss-making)	+11.99% (above 0%: growing)	n/m	−128.11% (below 0%: shrinking)	100.00%	(147.09%)
PCSA Heatwurx Inc.	$4.7M	1.6×	—	−64.29% (below 0%: shrinking)	n/m	+20.29% (above 0%: growing)	0.00%	0.00%	Compare
DRMA Dermata Therapeutics, Inc.	$4.5M	— (loss-making)	—	—	n/m	+9.99% (above 0%: growing)	0.00%	0.00%	Compare
ENLV Enlivex Ltd.	$4.5M	0.0×	—	—	n/m	+35.94% (above 0%: growing)	0.00%	0.00%	Compare
NCNA NuCana PLC Sponsored ADR	$4.4M	— (loss-making)	—	—	n/m	+55.66% (above 0%: growing)	0.00%	0.00%	Compare
ADTX Aditxt, Inc.	$4.4M	— (loss-making)	—	+1,120.00% (above 0%: growing)	n/m	+60.82% (above 0%: growing)	23.77%	(35,753.28%)	Compare
AZTR Azitra, Inc.	$4.3M	1.0×	— (loss-making)	−93.38% (below 0%: shrinking)	n/m	−19.55% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$4.5M	1.0×	—	−36.73%	—	+28.12%	0.00%	0.00%

All 614 Biotechnology stocks →

Xenetic Biosciences, Inc. (XBIO) key facts

Strength: Xenetic Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 19.0% from fiscal 2024.
Xenetic Biosciences, Inc. (XBIO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, XBIO traded at $1.98, a market capitalization of $4.7 million.
Return on equity was −40.0% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −30.91 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.